Cellectis S.A. | Mid-cap | Healthcare
€2.99
-1.48%
| Cellectis S.A Stock Comparison:
Cellectis S.A vs Abivax SACellectis S.A vs Medincell S.ACellectis S.A vs Valneva SECellectis S.A vs NanobiotixCellectis S.A vs Inventiva S.ACellectis S.A vs CAC 40 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 14.2M
Gross Profit 12.2M 85.50%
Operating Income -8.2M -57.32%
Net Income -20.2M -141.91%

Balance Sheet Metrics

Total Assets 301.5M
Total Liabilities 218.8M
Shareholders Equity 82.7M
Debt to Equity 2.64

Cash Flow Metrics

Operating Cash Flow -16.1M
Free Cash Flow -9.0M

Revenue & Profitability Trend

Cellectis S.A Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i35.4M755.0K19.2M30.3M51.1M
Cost of Goods Sold i7.8M737.0K1.8M1.8M2.0M
Gross Profit i27.5M18.0K17.4M28.5M49.1M
Gross Margin % i77.9%2.4%90.8%93.9%96.2%
Operating Expenses
Research & Development i77.1M87.6M97.5M117.8M77.0M
Selling, General & Administrative i7.2M16.8M17.5M22.9M22.5M
Other Operating Expenses i-7.3M-556.0K-1.4M-499.0K289.0K
Total Operating Expenses i77.0M103.9M113.6M140.2M99.9M
Operating Income i-50.7M-97.3M-89.7M-103.5M-42.3M
Operating Margin % i-143.5%-12,887.7%-467.7%-341.0%-82.9%
Non-Operating Items
Interest Income i9.6M3.6M1.1M719.0K1.4M
Interest Expense i6.3M5.3M3.8M4.2M2.4M
Other Non-Operating Income16.2M-16.4M6.1M9.7M-10.6M
Pre-tax Income i-31.3M-116.5M-98.6M-96.8M-53.6M
Income Tax i0371.0K87.0K00
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-31.3M-108.4M-114.0M-125.1M-97.5M
Net Margin % i-88.6%-14,363.3%-594.8%-412.3%-190.9%
Key Metrics
EBITDA i-24.2M-76.3M-82.4M-88.2M-32.8M
EPS (Basic) i€-0.41€-1.77€-2.33€-1.91€-1.91
EPS (Diluted) i€-0.41€-1.77€-2.33€-1.91€-1.91
Basic Shares Outstanding i7715346862283535467734984358419343642029
Diluted Shares Outstanding i7715346862283535467734984358419343642029

Income Statement Trend

Cellectis S.A Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i122.0M136.7M89.8M185.6M241.1M
Short-term Investments i99.7M67.1M7.9M499.0K27.1M
Accounts Receivable i5.7M569.0K772.0K20.4M5.2M
Inventory i--001.6M
Other Current Assets253.9K345.0K538.0K50.0K12.2M
Total Current Assets i244.6M233.0M143.8M225.4M315.4M
Non-Current Assets
Property, Plant & Equipment i79.1M91.5M90.6M95.2M28.9M
Goodwill i949.9K672.0K718.0K1.9M1.6M
Intangible Assets i949.9K672.0K718.0K1.9M1.6M
Long-term Investments-----
Other Non-Current Assets10.2M-1.0K-3.0K-1.0K
Total Non-Current Assets i82.2M101.3M117.4M156.6M154.1M
Total Assets i326.7M334.3M261.2M382.1M469.5M
Liabilities
Current Liabilities
Accounts Payable i15.9M19.1M21.5M23.8M24.6M
Short-term Debt i11.3M13.7M12.8M10.6M6.7M
Current Portion of Long-term Debt-----
Other Current Liabilities10.7M978.0K15.7M1.3M6.1M
Total Current Liabilities i141.6M155.1M63.0M49.3M52.0M
Non-Current Liabilities
Long-term Debt i66.6M71.4M62.9M90.3M100.0M
Deferred Tax Liabilities i0158.0K---
Other Non-Current Liabilities751.4K12.9M7.0M1.9M4.6M
Total Non-Current Liabilities i73.5M94.4M72.3M96.3M108.6M
Total Liabilities i215.1M249.6M135.3M145.6M160.6M
Equity
Common Stock i5.0M4.4M3.0M2.9M2.8M
Retained Earnings i-280.8M-405.8M-439.5M-698.3M-587.0M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i111.6M84.7M125.9M236.5M308.8M
Key Metrics
Total Debt i77.9M85.1M75.8M100.9M106.7M
Working Capital i102.9M77.9M80.8M176.1M263.3M

Balance Sheet Composition

Cellectis S.A Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-31.3M-116.8M-98.7M-96.7M-53.6M
Depreciation & Amortization i16.9M18.5M18.4M14.2M7.8M
Stock-Based Compensation i2.7M5.2M6.0M11.5M10.0M
Working Capital Changes i45.7M48.9M-5.7M-12.3M-17.3M
Operating Cash Flow i15.8M-26.1M-71.2M-89.9M-39.3M
Investing Activities
Capital Expenditures i-2.2M-1.1M-2.4M-18.5M-44.1M
Acquisitions i-----
Investment Purchases i-138.7M---143.0K-2.1M
Investment Sales i54.4M-126.0K15.0M5.0M
Investing Cash Flow i-86.5M-2.7M-2.3M-3.7M-41.2M
Financing Activities
Share Repurchases i---569.0K--
Dividends Paid i00000
Debt Issuance i19.8M29.7M5.8M024.2M
Debt Repayment i-13.7M-16.2M-12.4M-10.6M-4.7M
Financing Cash Flow i76.6M81.4M-7.2M34.0M28.6M
Free Cash Flow i16.3M-25.8M-89.9M-123.1M-124.7M
Net Change in Cash i6.0M52.6M-80.7M-59.6M-51.8M

Cash Flow Trend

Cellectis S.A Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -7.41
Forward P/E -3.38
Price to Book 2.26
Price to Sales 4.81
PEG Ratio -3.38

Profitability Ratios

Profit Margin -93.00%
Operating Margin -52.69%
Return on Equity -48.02%
Return on Assets -7.43%

Financial Health

Current Ratio 1.38
Debt to Equity 93.67
Beta 3.07

Per Share Data

EPS (TTM) €-0.50
Book Value per Share €1.34
Revenue per Share €0.63

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
alcls305.0M-7.412.26-48.02%-93.00%93.67
Abivax SA 5.6B-25.79-94.87-499.78%0.00%-2.04
Medincell S.A 879.5M--112.65%-66.50%-4.11
Valneva SE 839.7M70.644.44-38.02%-34.15%105.63
Nanobiotix 819.6M-11.81-103.70%0.00%-0.07
Inventiva S.A 742.6M-1.63-21.80172.73%0.00%-14.91

Financial data is updated regularly. All figures are in the company's reporting currency.